Gilead Sciences reports $8.3 billion revenue for quarter ended September 30, 2026, up 6.8%

ยท GILD

Gilead Sciences reported revenue of $8.3 billion for the quarter ended September 30, 2026, an increase of 6.8% from the same quarter a year earlier ($7.77 billion).

For the same period it posted net income of $2.43 billion, down 20.4%, or $1.94 per diluted share (2.43 a year earlier).

That is a net margin of 29.3%.

On Sanad's AAOIFI Standard 21 screen, Gilead Sciences is currently compliant: interest-bearing debt is 12.4% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on October 30, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Gilead Sciences news